1412 related articles for article (PubMed ID: 32800530)
1. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
2. Exploiting Human NK Cells in Tumor Therapy.
Vacca P; Pietra G; Tumino N; Munari E; Mingari MC; Moretta L
Front Immunol; 2019; 10():3013. PubMed ID: 32010130
[TBL] [Abstract][Full Text] [Related]
3. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
4. NK Cells and Other Innate Lymphoid Cells in Hematopoietic Stem Cell Transplantation.
Vacca P; Montaldo E; Croxatto D; Moretta F; Bertaina A; Vitale C; Locatelli F; Mingari MC; Moretta L
Front Immunol; 2016; 7():188. PubMed ID: 27242795
[TBL] [Abstract][Full Text] [Related]
5. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.
Mariotti FR; Quatrini L; Munari E; Vacca P; Moretta L
Front Immunol; 2019; 10():910. PubMed ID: 31105707
[TBL] [Abstract][Full Text] [Related]
6. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
[TBL] [Abstract][Full Text] [Related]
7. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
[TBL] [Abstract][Full Text] [Related]
8. Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?
Vacca P; Munari E; Tumino N; Moretta F; Pietra G; Vitale M; Del Zotto G; Mariotti FR; Mingari MC; Moretta L
Immunol Lett; 2018 Sep; 201():14-19. PubMed ID: 30439479
[TBL] [Abstract][Full Text] [Related]
9. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
11. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
13. Helper Innate Lymphoid Cells-Unappreciated Players in Melanoma Therapy.
Garofalo C; Cerantonio A; Muscoli C; Mollace V; Viglietto G; De Marco C; Cristiani CM
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765891
[TBL] [Abstract][Full Text] [Related]
14. Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy.
Rethacker L; Roelens M; Bejar C; Maubec E; Moins-Teisserenc H; Caignard A
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810032
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
16. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
Zaghi E; Calvi M; Di Vito C; Mavilio D
Front Immunol; 2019; 10():2794. PubMed ID: 31849972
[TBL] [Abstract][Full Text] [Related]
17. Development of human natural killer cells and other innate lymphoid cells.
Montaldo E; Vacca P; Moretta L; Mingari MC
Semin Immunol; 2014 Apr; 26(2):107-13. PubMed ID: 24559836
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
